Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Learn from Prof. Seema Aceves about the interconnectivity of type 2 inflammation and barrier dysfunction in mediating EoE pathophysiology.

Learn how partnering with patients and considering the clinical relevance of symptom improvements can improve patient quality of life
Learn from Dr. Hirano and Dr. Marcon as they discuss how to unmask EoE symptoms that may be hidden by patients' coping mechanisms.
Dr. Dhandapani Ashok highlights treatment options for patients with EoE aged 12 years and younger and the importance of shared decision-making.

Dr. Reynold Panettieri discusses how IL-4 and IL-13 drive airway remodeling in type 2 asthma.

Highlights from the ADVENT educational symposium at EADV 2024 discussing the current understanding of the science and treatment landscape in bullous pemphigoid (BP).

Learn how FeNO, a noninvasive biomarker for type 2 inflammation, can be used to optimize care for asthma patients.
Join Dr. Nirmala Gonsalves as she reviews symptoms of EoE and tools to assess symptoms in patients with EoE.
Hear Dr. Ulrike von Arnim discuss the expert recommendations for monitoring patients with EoE in routine clinical practice.
Join Dr. Nirmala Gonsalves as she reviews some of the tools to assess quality-of-life outcomes in patients with EoE.

Presentation highlights from the ADVENT symposium at the EAACI 2023 congress in Hamburg, Germany.